Pasello, Giulia http://orcid.org/0000-0002-8741-6038
Fabricio, Aline S. C.
Del Bianco, Paola
Salizzato, Valentina
Favaretto, Adolfo
Piccin, Luisa
Zustovich, Fable
Fabozzi, Alessio
De Rossi, Costanza
Pigozzo, Jacopo
De Nuzzo, Mattia
Cappelletto, Elia
Bonanno, Laura
Palleschi, Dario
De Salvo, Gian Luca
Guarneri, Valentina
Gion, Massimo
Chiarion-Sileni, Vanna
Funding for this research was provided by:
Ministero della Salute (RF-2018-12367604)
Istituto Oncologico Veneto (5 x 1000 BIGID219SILE)
Article History
Received: 30 November 2023
Accepted: 20 January 2024
First Online: 5 March 2024
Declarations
:
: This study was conducted with the approval of the Ethics Committees of each institution involved, and carried out in accordance with the Declaration of Helsinki and the Good Clinical Practice. All participants signed the informed consent before entering the study.
: All patients consented to the publication of aggregated and anonymized data.
: VCS has advisory roles for Pierre-Fabre, Immuncore and Merck Sharp & Dohme and she received support for attending meetings and travel from Pierre Fabre and Sanofi. GP has advisory board membership, honoraria, speaker’s fees, consultant roles for Amgen, AstraZeneca, BMS, Eli Lilly, Jansenn, MSD, Novartis, Roche and she received unconditioned research support from AstraZeneca, Roche, MSD. LP received speaker’s fees from Novartis, MSD, BMS. AF<sup>6</sup> received speaker’s fees from BMS, MSD, Novartis, SUN Pharma. JP has advisory roles for MSD and received speaker's fees from BMS. LB received personal fees as an invited speaker and for advisory board membership from AstraZeneca, MSD, BMS, Roche, Novartis and Lilly; she is a member of the AstraZeneca Steering Committee, she received unconditioned research support from AstraZeneca. VG reports personal fees for advisory board membership for AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, Exact Sciences, Gilead, Merck Serono, MSD, Novartis, Pfizer, Olema Oncology, Pierre Fabre; personal fees as an invited speaker for AstraZeneca, Daiichi Sankyo, Eli Lilly, Exact Sciences, Gilead, GSK, Novartis, Roche and Zentiva; personal fees for expert testimony for Eli Lilly. All the other authors (ASCF, PDB, VS, AF<sup><b>4</b></sup>, FZ, CDR, MDN, EC, DP, GLDS, MG) declare that they have no competing interests.